Stephanie Disher, Director, Chief Executive Officer, on June 01, 2026, sold 25,652 shares in Atmus Filtration Technologies (ATMU) for $1,160,676. Following the Form 4 filing with the SEC, Disher has control over a total of 363,024 common shares of the company, with 363,024 shares held directly.
SEC Filing:
Andrew Reardon, Chief Legal Officer & Secretary, on June 01, 2026, sold 5,000 shares in Ligand Pharmaceuticals (LGND) for $1,135,316. Following the Form 4 filing with the SEC, Reardon has control over a total of 41,382 common shares of the company, with 41,382 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/886163/000200101126000083/xslF345X05/edgardoc.xml
J. E. Davis, Director, Chief Executive Officer and President, on June 01, 2026, sold 10,000 shares in Quest Diagnostics (DGX) for $1,941,400. Following the Form 4 filing with the SEC, Davis has control over a total of 132,423 common shares of the company, with 132,423 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1022079/000159983726000005/xslF345X05/wk-form4_1780439916.xml
Christopher Peetz, Director, Chief Executive Officer, on June 01, 2026, sold 30,000 shares in Mirum Pharmaceuticals (MIRM) for $2,875,103. Following the Form 4 filing with the SEC, Peetz has control over a total of 381,809 common shares of the company, with 194,309 shares held directly and 187,500 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1759425/000161474026000010/xslF345X05/form4-06022026_070609.xml